Abstracts Archive - Page 1582 of 2607 - ACR Meeting Abstracts

Abstract Number: 2921 • 2017 ACR/ARHP Annual Meeting
Improved Survival Following Renal Transplantation in Waitlisted Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Zachary S. Wallace², Na Lu³, Yuqing Zhang⁴ and Hyon K. Choi⁵, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Department of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis is a major complication of systemic lupus erythematosus (SLE), occurring in up to half all SLE patients and progressing to end-stage renal…
Abstract Number: 2922 • 2017 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis in Vulnerable Populations
Christine Peschken¹, Rebecca Gole², Carol A Hitchon³, David Robinson³, Ada Man⁴, Annaliese Tisseverasinghe⁴ and Hani El-Gabalawy⁴, ¹Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Lupus nephritis is a known predictor of mortality; we have previously shown an increased frequency of nephritis in North American Indian (NAI) and Asian…
Abstract Number: 2923 • 2017 ACR/ARHP Annual Meeting
A Propensity Score-Matched Study of Organ Damage in Patients with Systemic Lupus Erythematosus from the BLISS Long-Term Extension Trials Versus the Toronto Lupus Cohort: A Post Hoc Longitudinal Analysis
Murray Urowitz¹, Robert L. Ohsfeldt^2,3, Ron Wielage³, Kari A. Kelton³, Yumi Asukai⁴ and Sulabha Ramachandran⁵, ¹Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Texas A&M University, Texas, TX, ³Medical Decision Modeling Inc., Indianapolis, IN, ⁴GSK, Uxbridge, Middlesex, United Kingdom, ⁵Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA
Background/Purpose: Two Phase 3, randomized controlled trials (BLISS 52/76) studied the efficacy and safety of belimumab plus standard of care (SoC) in systemic lupus erythematosus…
Abstract Number: 2924 • 2017 ACR/ARHP Annual Meeting
Effect of Antimalarials over the Different Domains of the Damage INDEX in Latin American SLE Patients
Guillermo J. Pons-Estel¹, Daniel Wojdyla², Graciela S. Alarcón³, Rosa Maria Serrano⁴, Rosana Quintana⁴, Manuel Ugarte-Gil⁵, Victor Pimentel-Quiroz⁵, Enrique R Soriano⁶, Marina Scolnik⁷, Monica Sacnun⁴, José A. Gómez-Puerta⁸, Mario H. Cardiel⁹, Virginia Pascual-Ramos¹⁰, Ignacio Garcia de la Torre¹¹, Leonor Barile⁹, Luis H. Silveira¹², Mary Carmen Amigo¹³, Maria Josefina Sauza del Pozo¹⁴, Marlene Guibert-Toledano¹⁵, Gil A. Reyes¹⁶, Antonio Iglesias Gamarra¹⁷, Luis Alonso Gonzalez¹⁸, Rosa Chacón-Díaz¹⁹, Maria H Esteva Spinetti²⁰, Isaac Abadi²⁰, Eduardo M. Acevedo-Vásquez²¹, Jose Alfaro-Lozano²², Maria Ines Segami²³, Loreto Massardo²⁴, Oscar Neira²⁵, Emilia Sato²⁶, Eloisa Bonfa²⁷, Lilian Costallat²⁸, Ricardo Xavier²⁹, Fernando Cavalcanti³⁰, Nilizio A. Da Silva³¹, Eduardo Ferreira Borba³², Luis J. Catoggio³³, Joao C. Tavares Brenol²⁹, Verónica Saurit³⁴, Francisco Caeiro³⁵, Alejandro Alvarellos³⁴, Judith Sarano³⁶, Mercedes Garcia³⁷, Laura Onetti³⁸, Cristina Drenkard³⁹, Guillermo Berbotto⁴⁰, Hugo R. Scherbarth⁴¹, Sergio Jacobelli²⁴, Jose F Molina⁴², Gloria Vásquez⁴² and Bernardo Pons-Estel⁴³, ¹GLADEL, Rosario, Argentina, ²GLADEL consultant, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Argentina, GLADEL, Rosario, Argentina, ⁵Peru, GLADEL, Lima, Peru, ⁶Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁸Colombia, GLADEL, Medellín, Colombia, ⁹GLADEL, Mexico, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico, ¹¹Hospital General de Occidente, Guadalajara, Mexico, ¹²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ¹³Centro Medico ABC, Mexico, Mexico, ¹⁴Servicio de Reumatología, Instituto Mexicano de Seguro Social, Hospital de Especialidades Nº 25, Monterrey, Mexico, ¹⁵Centro de Investigaciones Médico Quirúrgicas, Habana, Centro de Investigaciones Médico Quirúrgicas, Habana, La Habana, Cuba, ¹⁶GLADEL, Havana, Cuba, ¹⁷Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, medellin, Colombia, ¹⁸Medicarte IPS, Medellín, Colombia, ¹⁹Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ²⁰GLADEL, Caracas, Venezuela (Bolivarian Republic of), ²¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ²²Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²³GLADEL, Lima, Peru, ²⁴GLADEL, Santiago, Chile, ²⁵Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ²⁶Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²⁷Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁸GLADEL, Brazil, Brazil, ²⁹GLADEL, Porto Alegre, Brazil, ³⁰GLADEL, Pernambuco, Brazil, ³¹GLADEL, Goias, Brazil, ³²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³³Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³⁴Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³⁶Rheumatology Unit, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³⁷Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ³⁸GLADEL, Cordoba, Argentina, ³⁹Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴⁰Sanatorio Británico, Rosario, Argentina, ⁴¹GLADEL, Mar del Plata, Argentina, ⁴²GLADEL, Medellin, Colombia, ⁴³GLADEL, Rosario, Santa Fe, Argentina
Background/Purpose: We have previously shown that Latin American SLE patients treated with Antimalarials (AMs) have a 25% lower risk of damage accrual than patients not…
Abstract Number: 2925 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann E. Clarke¹, Ian N. Bruce², Murray Urowitz³, John G. Hanly⁴, Yvan St.Pierre⁵, Sang-Cheol Bae⁶, Sasha Bernatsky⁷, Dafna D Gladman⁸, Jorge Sanchez-Guerrero⁹, Paul R. Fortin¹⁰, Juanita Romero-Diaz¹¹, Michelle Petri¹², Rosalind Ramsey-Goldman¹³, Cynthia Aranow¹⁴, Søren Jacobsen¹⁵, Daniel J. Wallace¹⁶, Joan T. Merrill¹⁷, S. Sam Lim¹⁸, Ola Nived¹⁹, Andreas Jönsen²⁰, Susan Manzi²¹, Thomas Stoll²², Christine A. Peschken²³, David A. Isenberg²⁴, Anisur Rahman²⁵, Li Su²⁶ and Vernon Farewell²⁷, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Centre for Prongosis Studies in The Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ¹⁰Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ¹¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ¹²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹³FSM, Northwestern University, Chicago, IL, ¹⁴Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Department of Rheumatology, University Hospital, Lund, Sweden, ²⁰Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ²¹Medicine, Allegheny Health Network, Pittsburgh, PA, ²²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ²³RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²⁶Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ²⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Little is known about the association of healthcare costs and damage accrual. We describe the costs associated with damage progression using multi-state modeling. Methods:…
Abstract Number: 2926 • 2017 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Ellen Cealey¹, Pei-Suen Tsou¹, Ray A. Ohara¹, Yuxuan Du², Jonatan Hervoso¹, Nicholas Lepore¹, Sarah Arwani¹, Dinesh Khanna¹, David A. Fox¹ and M. Asif Amin¹, ¹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ²Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by dysregulated fibrosis of the skin. During fibrosis, macrophage release of transforming growth factor (TGF-β)…
Abstract Number: 2927 • 2017 ACR/ARHP Annual Meeting
Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Minghua Wu¹, Gloria Salazar¹, Jun Ying¹, Julio Charles², Xiaodong Zhou³, Maureen D. Mayes² and Shervin Assassi², ¹Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, TX, ³Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Previous global gene expression studies of SSc patients revealed presence of a prominent type I interferon (IFN) signature. IRF7 is a key transcription factor…
Abstract Number: 2928 • 2017 ACR/ARHP Annual Meeting
STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis
Debomita Chakraborty¹, Barbora Šumová², Tatjana Mallano³, Chih-Wei Chen³, Alfiya Distler³, Christina Bergmann³, Andreas Ramming⁴, Oliver Distler⁵, Georg Schett³, Ladislav Senolt⁶ and Jörg Distler³, ¹Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates key cellular processes such as proliferation, apoptosis, invasion, angiogenesis, metastasis…
Abstract Number: 2929 • 2017 ACR/ARHP Annual Meeting
WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β
Chih-Wei Chen¹, Thuong Trinh-Minh², Neng-Yu Lin², Yun Zhang³, Florian Groeber⁴, Christian Beyer⁵, Georg Schett⁶ and Jörg Distler⁷, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Translational Center Würzburg, Fraunhofer Ins. IGB, Würzburg, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Canonical Wnt/β-catenin signaling has emerged as a core pathway of fibrosis. They role of non-canonical Wnt signaling, however, has not been systematically studied. In…
Abstract Number: 2930 • 2017 ACR/ARHP Annual Meeting
Transforming Growth Factor Beta 3 (TGFB3) – a Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium
Pravitt Gourh¹, Elaine F. Remmers², Ansuman Satpathy³, Steven Boyden⁴, Nadia D. Morgan⁵, Ami A. Shah⁶, Adebowale Adeyemo², Amy Bentley², Mary A. Carns⁷, Settara C Chandrasekharappa², Lorinda Chung⁸, Lindsey A. Criswell⁹, Chris T. Derk¹⁰, Robyn T. Domsic¹¹, Ayo Doumatey², Heather Gladue¹², Avram Goldberg¹³, Jessica K. Gordon¹⁴, Vivien Hsu¹⁵, Reem Jan¹⁶, Dinesh Khanna¹⁷, Maureen D. Mayes¹⁸, Thomas A. Medsger Jr.¹⁹, Maxwell Mumbach³, Paula S. Ramos²⁰, Marcin Trojanowski²¹, Lesley Ann Saketkoo²², Elena Schiopu¹⁷, Victoria K. Shanmugam²³, Daniel Shriner², Richard M. Silver²⁴, Virginia D. Steen²⁵, Antonia Valenzuela²⁶, John Varga²⁷, Howard Chang³, Charles Rotimi², Fredrick M. Wigley²⁸, Francesco Boin²⁹ and Daniel L. Kastner³⁰, ¹NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ³Stanford University, Stanford, CA, ⁴National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁸Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹³NYU Langone Medical Center, New York, NY, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁶Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas McGovern Medical School, Houston, TX, ¹⁹Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, ²⁰Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²¹Boston University, Boston, MA, ²²Tulane, New Orleans, LA, ²³Rheumatology, The George Washington University, Washington, DC, ²⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²⁵Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²⁶Stanford University School of Medicine, Stanford, CA, ²⁷Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁸Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁹Rheumatology, University California, San Francisco, San Francisco, CA, ³⁰Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is a multisystem disease that has a higher prevalence in African Americans (AA), with a more severe phenotype, internal organ involvement,…
Abstract Number: 2931 • 2017 ACR/ARHP Annual Meeting
Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems
Bhaven K. Mehta¹, Jennifer Franks², Guoshuai Cai², Diana Toledo³, Tammara A. Wood², Kimberly A. Archambault¹, Noelle Kosarek¹, Kathleen Kolstad⁴, Marianna Stark⁵, Antonia Valenzuela⁶, David Fiorentino⁷, Nielsen Fernandez-Becker⁸, Laren Becker⁸, Linda Nguyen⁸, John Clarke⁹, Francesco Boin¹⁰, Paul Wolters¹¹, Lorinda Chung¹² and Michael L. Whitfield¹, ¹Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Rheumatology, Stanford University Medical Center, Stanford, CA, ⁵Stanford University, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, CA, ⁷Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Gastroenterology & Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁹Medicine/Gastroenterology, Stanford University, Stanford, CA, ¹⁰Rheumatology, University California, San Francisco, San Francisco, CA, ¹¹Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, ¹²Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: While skin fibrosis is a hallmark of systemic sclerosis (SSc), internal organ involvement is the primary cause of morbidity and mortality, often related to…
Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Jérôme Hadjadj¹, Guillaume Canaud², Tristan Mirault³, Maxime Samson⁴, Patrick Bruneval⁵, Alexis Regent⁶, Claire Goulvestre⁷, Veronique Witko-Sarsat⁸, Nathalie Costedoat-Chalumeau⁹, Loïc Guillevin for the French Vasculitis Study Group¹⁰, Luc Mouthon¹¹ and Benjamin Terrier¹², ¹Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, Paris, France, Paris, France, ²Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, ³Department of Vascular Medicine, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France, ⁴Dijon University Hospital, Dijon, France, ⁵HEGP, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁷Department of Immunology, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁸Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, LABEX Inflamex, Université Sorbonne Paris Cité, 75013, Paris, France, Paris, France, ⁹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ¹²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…
Abstract Number: 2933 • 2017 ACR/ARHP Annual Meeting
The Microvascular Niche Instructs Pathogenic T Cells in Medium and Large Vessel Vasculitis
Cornelia M. Weyand¹, Zhenke Wen², Yi Shen², Gerald Berry³, Joyce Liao⁴ and Jorg Goronzy⁵, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Pathology, Stanford University School of Medicine, Stanford, CA, ⁴Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ⁵Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Adventitial microvascular networks (vasa vasora) control the access to the wall structure of medium and large arteries and thus guard the immune privilege of…
Abstract Number: 2934 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD)
Cornelia M. Weyand¹, Ryu Watanabe², Tsuyoshi Shirai³, Hui Zhang⁴, Gerald Berry⁵ and Jorg Goronzy⁶, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁴Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁵Pathology, Stanford University School of Medicine, Stanford, CA, ⁶Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Macrophages are key effector cells in the vessel wall inflammation of the atherosclerotic plaque as well as in the intramural infiltrates of giant cell…
Abstract Number: 2935 • 2017 ACR/ARHP Annual Meeting
Nasal Microbiota in Patients with Granulomatosis with Polyangiitis Compared to Healthy Controls
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem¹, Peter C. Grayson², Chunyu Zhao³, Kyle Bittinger³, Ronald G. Collman⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ³Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Medicine & Microbiology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have suggested a potential link between nasal microbes, in particular Staphylococcus aureus, and granulomatosis with polyangiitis (GPA; Wegener’s) but these studies relied…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].